Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / HighVista Strategies LLC
Form 13F · Q2 2026

HighVista Strategies LLC

CIK 1335325Filed 2026-08-1413F-HR View the filing on EDGAR ↗
$439M
Reported book value
147
Positions
12
Quarters on record
Top 50
Positions

HighVista Strategies LLC — holdings

Top 50 positions of 147, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1IVZ Invesco Db Commdy Indx Trck1.1M+0.0%$28M6.4%
2ABIVAX SA Abivax Sa113,031−0.2%$15M3.4%
3RVMD Revolution Medicines Inc66,983−3.4%$13M2.9%
4DFTX Definium Therapeutics Inc242,884+30.7%$11M2.6%
5IMVT Immunovant Inc277,873+23.4%$11M2.4%
6PRAX Praxis Precision Medicines I30,210+14.8%$10M2.3%
7RLAY Relay Therapeutics Inc506,235+20.0%$9M2.2%
8ALKS Alkermes Plc179,256+144.9%$9M2.1%
9PCVX Vaxcyte Inc149,739+20.1%$9M2.0%
10TNGX Tango Therapeutics Inc260,070+149.6%$8M1.9%
11LQDA Liquidia Corporation97,896−1.9%$8M1.8%
12COGT Cogent Biosciences Inc188,780−4.2%$7M1.7%
13GPCR Structure Therapeutics Inc130,784+5.5%$7M1.6%
14ELVN Enliven Therapeutics Inc137,866+88.6%$7M1.6%
15AMLX Amylyx Pharmaceuticals Inc386,080+9.7%$7M1.6%
16SYRE Spyre Therapeutics Inc77,807−46.8%$7M1.6%
17LBRX Lb Pharmaceuticals Inc211,511+21.8%$7M1.6%
18CYTK Cytokinetics Inc78,003+33.0%$7M1.5%
19CCCC C4 Therapeutics Inc1.3M—$6M1.4%
20TYRA Tyra Biosciences Inc184,774+40.7%$6M1.3%
21ALMS Alumis Inc199,968+77.1%$6M1.3%
22PHVS Pharvaris N V160,494+64.0%$6M1.3%
23TARS Tarsus Pharmaceuticals Inc87,060+65.9%$5M1.2%
24CMPS Compass Pathways Plc371,120+1.9%$5M1.2%
25DNTH Dianthus Therapeutics Inc51,125+43.7%$5M1.1%
26NRIX Nurix Therapeutics Inc203,739−10.1%$5M1.1%
27AXSM Axsome Therapeutics Inc.20,183−1.2%$5M1.1%
28TVTX Travere Therapeutics Inc86,233+137.4%$5M1.1%
29VERA Vera Therapeutics Inc105,907+53.0%$5M1.0%
30NVDA Nvidia Corporation21,792−2.8%$4M1.0%
31GHRS Gh Research Plc158,770−25.5%$4M1.0%
32PALI Palisade Bio Inc2.0M+0.6%$4M1.0%
33ARGX Argenx Se4,561−7.3%$4M1.0%
34MAZE Maze Therapeutics Inc136,572+36.8%$4M0.9%
35OCUL Ocular Therapeutix Inc408,534−7.5%$4M0.9%
36ORKA Oruka Therapeutics Inc41,902−46.9%$4M0.9%
37DYN Dyne Therapeutics Inc171,961−6.0%$4M0.9%
38EWTX Edgewise Therapeutics Inc90,996−1.0%$4M0.8%
39MLTX Moonlake Immunotherapeutics187,946−3.1%$4M0.8%
40INSM Insmed Inc31,256+28.5%$3M0.8%
41CLDX Celldex Therapeutics Inc New86,964−2.7%$3M0.7%
42AMZN Amazon Com Inc13,397−40.2%$3M0.7%
43IVA Inventiva Sa831,442+35.0%$3M0.7%
44TLN Talen Energy Corp8,148+161.3%$3M0.7%
45RLMD Relmada Therapeutics Inc445,799—$3M0.7%
46PTGX Protagonist Therapeutics Inc24,460−27.7%$3M0.7%
47ERAS Erasca Inc160,328−11.5%$3M0.7%
48VRDN Viridian Therapeutics Inc159,885+19.1%$3M0.7%
49HPE Hewlett Packard Enterprise C59,081−34.3%$3M0.6%
50MLYS Mineralys Therapeutics Inc86,085+84.0%$2M0.5%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.